References
1. Franz CC, Egger S, Born C, Rätz Bravo AE, Krähenbühl S. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. European journal of clinical pharmacology 2012;68:179-188.
2. Franz CC, Hildbrand C, Born C, Egger S, Rätz Bravo AE, Krähenbühl S. Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations. European journal of clinical pharmacology 2013;69:1565-1573.
3. Rodighiero V. Effects of liver disease on pharmacokinetics. Clinical pharmacokinetics 1999;37:399-431.
4. Nevzorova YA, Boyer-Diaz Z, Cubero FJ, Gracia-Sancho J. Animal models for liver disease–A practical approach for translational research. Journal of hepatology 2020;73:423-440.
5. Guillouzo A. Liver cell models in in vitro toxicology. Environmental health perspectives 1998;106:511-532.
6. Du Y, Polacheck WJ, Wells RG: Bile Duct-on-a-Chip. In: Organ-on-a-Chip: Springer, 2022; 57-68.
7. Hassan S, Sebastian S, Maharjan S, Lesha A, Carpenter A-M, Liu X, Xie X, et al. Liver-on-a-chip models of fatty liver disease. Hepatology (Baltimore, Md.) 2020;71:733.
8. Melgert BN, Olinga P, Weert B, Slooff MJ, Meijer DK, Poelstra K, Groothuis GM. Cellular distribution and handling of liver-targeting preparations in human livers studied by a liver lobe perfusion. Drug metabolism and disposition 2001;29:361-367.
9. Schreiter T, Marquitan G, Darnell M, Sowa J-P, Bröcker-Preuss M, Andersson TB, Baba HA, et al. An ex vivo perfusion system emulating in vivo conditions in noncirrhotic and cirrhotic human liver. Journal of Pharmacology and Experimental Therapeutics 2012;342:730-741.
10. Villeneuve JP, Huet PM, Gariepy L, Fenyves D, Willems B, Cǒté J, Lapointe R, et al. Isolated perfused cirrhotic human liver obtained from liver transplant patients: a feasibility study. Hepatology 1990;12:257-263.
11. van Rijn R, Schurink IJ, de Vries Y, van den Berg AP, Cortes Cerisuelo M, Darwish Murad S, Erdmann JI, et al. Hypothermic machine perfusion in liver transplantation—a randomized trial. New England Journal of Medicine 2021;384:1391-1401.
12. Stopfer P, Giessmann T, Hohl K, Hutzel S, Schmidt S, Gansser D, Ishiguro N, et al. Optimization of a drug transporter probe cocktail: potential screening tool for transporter‐mediated drug–drug interactions. British journal of clinical pharmacology 2018;84:1941-1949.
13. de Vries Y, Matton AP, Nijsten MW, Werner MJ, van den Berg AP, de Boer MT, Buis CI, et al. Pretransplant sequential hypo‐and normothermic machine perfusion of suboptimal livers donated after circulatory death using a hemoglobin‐based oxygen carrier perfusion solution. American journal of transplantation 2019;19:1202-1211.
14. Brüggenwirth IM, van Leeuwen OB, Porte RJ, Martins PN. The emerging role of viability testing during liver machine perfusion. Liver Transplantation 2021.
15. Mergental H, Stephenson BT, Laing RW, Kirkham AJ, Neil DA, Wallace LL, Boteon YL, et al. Development of clinical criteria for functional assessment to predict primary nonfunction of high‐risk livers using normothermic machine perfusion. Liver Transplantation 2018;24:1453-1469.
16. van Leeuwen OB, de Vries Y, Fujiyoshi M, Nijsten MW, Ubbink R, Pelgrim GJ, Werner MJ, et al. Transplantation of high-risk donor livers after ex situ resuscitation and assessment using combined hypo-and normothermic machine perfusion: a prospective clinical trial. Annals of surgery 2019;270:906-914.
17. Boteon YL, Laing RW, Schlegel A, Wallace L, Smith A, Attard J, Bhogal RH, et al. Combined hypothermic and normothermic machine perfusion improves functional recovery of extended criteria donor livers. Liver transplantation 2018;24:1699-1715.
18. Eshmuminov D, Becker D, Bautista Borrego L, Hefti M, Schuler MJ, Hagedorn C, Muller X, et al. An integrated perfusion machine preserves injured human livers for 1 week. Nature biotechnology 2020;38:189-198.
19. Op den Dries S, Karimian N, Sutton M, Westerkamp A, Nijsten M, Gouw A, Wiersema‐Buist J, et al. Ex vivo normothermic machine perfusion and viability testing of discarded human donor livers. American Journal of Transplantation 2013;13:1327-1335.
20. Bosch J, García-Pagán JC. Complications of cirrhosis. I. Portal hypertension. Journal of hepatology 2000;32:141-156.
21. Stevens LJ, Zhu AZ, Chothe PP, Chowdhury SK, Donkers JM, Vaes WH, Knibbe CA, et al. Evaluation of normothermic machine perfusion of porcine livers as a novel preclinical model to predict biliary clearance and transporter-mediated drug-drug interactions using statins. Drug Metabolism and Disposition 2021;49:780-789.
22. Bergman E, Forsell P, Tevell A, Persson EM, Hedeland M, Bondesson U, Knutson L, et al. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. European journal of pharmaceutical sciences 2006;29:205-214.
23. Hebert MF. Impact of pregnancy on maternal pharmacokinetics of medications. Clinical pharmacology during pregnancy 2013:17-39.
24. Rane A, Wilkinson G, Shand D. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. Journal of Pharmacology and Experimental Therapeutics 1977;200:420-424.
25. Delco F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S. Dose adjustment in patients with liver disease. Drug safety 2005;28:529-545.
26. Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clinical pharmacokinetics 2010;49:189-206.
27. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clinical therapeutics 2003;25:2822-2835.
28. Iisalo E. Clinical pharmacokinetics of digoxin. Clinical pharmacokinetics 1977;2:1-16.
29. Doherty JE, Flanigan W, Murphy M, Bulloch R, Dalrymple G, Beard O, Perkins W, et al. Tritiated digoxin: XIV. Enterohepatic circulation, absorption, and excretion studies in human volunteers. Circulation 1970;42:867-873.
30. Ben-Itzhak J, Bassan HM, Shor R, Lanir A. Digoxin quinidine interaction: a pharmacokinetic study in the isolated perfused rat liver. Life sciences 1985;37:411-415.
31. Beermann B, Dalen E, Lindström B, Rosen A. On the fate of furosemide in man. European journal of clinical pharmacology 1975;9:57-61.
32. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong J, Furlong TJ, et al. Clinical pharmacokinetics of metformin. Clinical pharmacokinetics 2011;50:81-98.
33. Erlinger S. Bile secretion. British medical bulletin 1992;48:860-876.
34. Mori D, Kashihara Y, Yoshikado T, Kimura M, Hirota T, Matsuki S, Maeda K, et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug metabolism and pharmacokinetics 2019;34:78-86.
35. Prueksaritanont T, Tatosian D, Chu X, Railkar R, Evers R, Chavez‐Eng C, Lutz R, et al. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clinical Pharmacology & Therapeutics 2017;101:519-530.
36. Takehara I, Yoshikado T, Ishigame K, Mori D, Furihata K-i, Watanabe N, Ando O, et al. Comparative study of the dose-dependence of OATP1B inhibition by rifampicin using probe drugs and endogenous substrates in healthy volunteers. Pharmaceutical research 2018;35:1-13.
37. Eurotransplant. Transplants in 2021, by country, by donor type, by organ type. In: Statistics Report Library; 2022.
38. Thakkar N, Slizgi JR, Brouwer KL. Effect of liver disease on hepatic transporter expression and function. Journal of pharmaceutical sciences 2017;106:2282-2294.
39. Drozdzik M, Szelag‐Pieniek S, Post M, Zeair S, Wrzesinski M, Kurzawski M, Prieto J, et al. Protein abundance of hepatic drug transporters in patients with different forms of liver damage. Clinical Pharmacology & Therapeutics 2020;107:1138-1148.
40. Billington S, Ray AS, Salphati L, Xiao G, Chu X, Humphreys WG, Liao M, et al. Transporter expression in noncancerous and cancerous liver tissue from donors with hepatocellular carcinoma and chronic hepatitis C infection quantified by LC-MS/MS proteomics. Drug Metabolism and Disposition 2018;46:189-196.
41. Wang L, Collins C, Kelly EJ, Chu X, Ray AS, Salphati L, Xiao G, et al. Transporter expression in liver tissue from subjects with alcoholic or hepatitis C cirrhosis quantified by targeted quantitative proteomics. Drug Metabolism and Disposition 2016;44:1752-1758.
42. Weersink RA, Bouma M, Burger DM, Drenth JP, Hunfeld NG, Kranenborg M, Monster-Simons MH, et al. Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. BMJ open 2016;6:e012991.
43. Clark T, Bau L, Dengu F, Voyce D, Carlisle R, Friend P, Coussios C. Predicting clinical pharmacokinetics and toxicity of current and emerging oncology therapeutics by normothermic perfusion of isolated human-sized organs. In: AACR; 2021.
44. Goumard C, Turco C, Sakka M, Aoudjehane L, Lesnik P, Savier E, Conti F, et al. Ex-Vivo Pharmacological Defatting of the Liver: A Review. Journal of Clinical Medicine 2021;10:1253.
45. Mazilescu LI, Selzner M, Selzner N. Defatting strategies in the current era of liver steatosis. JHEP Reports 2021;3:100265.
46. Rigo F, Navarro-Tableros V, De Stefano N, Calleri A, Romagnoli R: Ex vivo normothermic hypoxic rat liver perfusion model: an experimental setting for organ recondition and pharmacological intervention. In: In Vitro Models for Stem Cell Therapy: Springer, 2021; 139-150.
47. Franzin R, Stasi A, Fiorentino M, Simone S, Oberbauer R, Castellano G, Gesualdo L. Renal Delivery of Pharmacologic Agents During Machine Perfusion to Prevent Ischaemia-Reperfusion Injury: From Murine Model to Clinical Trials. Frontiers in Immunology 2021;12:2687.
48. Butler AJ, Rees MA, Wight DG, Casey ND, Alexander G, White DJ, Friend PJ. Successful extracorporeal porcine liver perfusion for 72 hr1. Transplantation 2002;73:1212-1218.
49. Liu Q, Nassar A, Buccini L, Iuppa G, Soliman B, Pezzati D, Hassan A, et al. Lipid metabolism and functional assessment of discarded human livers with steatosis undergoing 24 hours of normothermic machine perfusion. Liver Transplantation 2018;24:233-245.
50. Vogel T, Brockmann JG, Pigott D, Neil DA, Muthusamy ASR, Coussios CC, Friend PJ. Successful transplantation of porcine liver grafts following 48-hour normothermic preservation. PLoS One 2017;12:e0188494.
51. Sharma AK, Laubach VE. Protecting donor livers during normothermic machine perfusion with stem cell EVs. Transplantation 2018;102:725.